Hepatology 25 : 772774
As more individuals face health risks associated with excess weight, the demand for GLP-1 receptor agonist, proven to reduce weight, improve glycemic control and lower cardiometabolic risk, is expected to rise substantially, thereby driving the growth of the GLP-1 receptor agonist market
Oral semaglutide, available at $289/mo (or $249/mo on the 6-month plan), bypasses the stomach's delayed-emptying mechanism entirely and produces fewer digestive side effects for some patients, though individual absorption varies
Administration should occur only under the supervision of a licensed healthcare professional with appropriate patient evaluation, documentation, and informed consent
Additionally, it suppresses glucagon secretion , a hormone that raises blood sugar levels, thereby preventing excessive glucose production by the liver
While those numbers are worth noting, theyre comparable to or lower than what is observed with Semaglutide (which saw 7-11% discontinuation across trial arms) and suggest manageable tolerability for most participants